Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term rollover platform safety study for Janssen hematologic oncology agents
jRCT2041240191Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2025
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Open-label trial of JNJ-64264681, JNJ-67856633, ibrutinib, rezetamig, JNJ-74856665 and 2 more in acute myeloid leukemia (AML), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mature B-cell lymphoma (7 arms), sponsored by Janssen Pharmaceutical. Started Feb 2025; status: active, not recruiting.
02
Drugs
JNJ-64264681JNJ-67856633ibrutinibrezetamigJNJ-74856665
03
Conditions
acute myeloid leukemia (AML)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mature B-cell lymphoma
Beyond the preview
Go deeper on jRCT2041240191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240191.